We help pharma, medtech, diagnostics and digital-health companies turn an authorization into actual reimbursement, real distribution and a local presence the market trusts — in both directions: international companies entering Germany and the EU, and German companies going to market abroad.
Germany is the largest and most regulated healthcare market in the EU. The skill that gets a foreign company into it is the same skill that takes a German company out — reading a regulated market and turning approval into revenue. Mirror image, one team.
We move foreign pharma, medtech and digital health through German authorization, reimbursement and distribution. Germany first; the EU from there.
We help German manufacturers, hospitals and labs take products and equipment to foreign markets — target-market regulation, partners, channels and local representation.
Getting authorized and getting paid are two different projects. We handle the second one — the part where most entrants stall.
What decides your revenue happens after the approval or CE mark: the reimbursement decision, the negotiated price, the distribution channel, and the relationships that payers, hospitals and partners expect before they commit. In Germany, that work is structure before visibility — choose the right regulatory route, commercial model and local presence first; the market reads everything else from there.
The “how to enter a market” layer is commodity — free from trade agencies and now answered by AI. The defensible layer is regulated market access, execution, and named people accountable for the outcome.
Not “advice on how to enter a market,” but a business carried through regulation and reimbursement — with local presence and personal accountability for the result. In both directions.
Drugs, devices, diagnostics and digital health each follow a different regulatory and reimbursement logic. We keep them separate — pretending one playbook covers all three is exactly what a generalist would do.
Reimbursement strategy under AMNOG and the G-BA / IQWiG benefit assessment, the right commercial model, distribution and local representation.
Pharma →MDR / IVDR pathway and CE marking, Notified Body coordination, hospital and tender access, distribution partners and equipment.
Medtech →Germany's “app on prescription” route: BfArM fast-track, the data-security bar, and the part nobody tells you — turning a listing into actual prescriptions.
Digital Health →We also support adjacent regulated sectors (energy & cleantech, chemicals / REACH) and handle straightforward market entry in other industries — but life sciences is where we go deepest.
The value is in execution and the relationships behind it — that's the layer we own. The same four steps run in both directions; only the target market changes.
Where you actually fit: reimbursement scenario, segment, comparator, entry model.
We identify and approach the right partners, payers and hospital contacts — not the ones who merely hold a business card.
Meetings, negotiations and correspondence in the proper local language. We represent you on the ground.
A continuing local presence, so relationships stay warm and the market keeps taking your calls.
A boutique that claims to do regulatory affairs, benefit dossiers, distribution and law all in-house isn't credible to anyone who has launched a product. Owning the right layer and orchestrating the rest is.
Executed with specialist partners, kept aligned to the commercial goal and your timeline — so nothing falls between the desks.
A focused working session plus a short written output — so you know the realistic picture before committing budget. Sector-specific, done in days, in either direction.
Makers of drugs, devices, diagnostics and digital-health products from abroad, for whom Germany is the first serious step into the EU — where the entry barrier is real and a local guide is not optional.
German pharma, medtech, device and equipment makers, clinics and laboratories that need to reach foreign markets — with their regulation, partners and channels handled.
Book a focused session, and leave with a realistic scenario, a commercial model and a partner shortlist.
Book a Market Access Session →